Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC
The Food and Drug Administration (FDA) has granted accelerated approval to Exkivity (mobocertinib) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations,…